ArticleJournal of ophthalmology2013
Visual performance in patients with neovascular age-related macular degeneration undergoing treatment with intravitreal ranibizumab.
Article in Journal of ophthalmology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- PLFest: A New Platform for Accessible, Reproducible, and Open Perceptual Learning Research.Journal of cognitive enhancement : towards the integration of theory and practice · 2024Article
- Article
- Two-Photon Vision in Age-Related Macular Degeneration: A Translational Study.Diagnostics (Basel, Switzerland) · 2022Article
- Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes.Journal of clinical medicine · 2021Article
- Development and Validation of a Smartphone-based Contrast Sensitivity Test.Translational vision science & technology · 2019Article
- Mesopic and Dark-Adapted Two-Color Fundus-Controlled Perimetry in Choroidal Neovascularization Secondary to Age-Related Macular Degeneration.Translational vision science & technology · 2019Article
- Comparison of two devices to simulate vision with intraocular lenses.Clinical ophthalmology (Auckland, N.Z.) · 2019Article
- Retinal accumulation of zeaxanthin, lutein, and β-carotene in mice deficient in carotenoid cleavage enzymes.Experimental eye research · 2017Article
- Evaluation of the precision of contrast sensitivity function assessment on a tablet device.Scientific reports · 2017Article
- Performance of a differential contrast sensitivity method to measure intraocular scattering.Biomedical optics express · 2017Article
- Visual Function and Its Relationship with Severity of Early, and Activity of Neovascular, Age-Related Macular Degeneration.Journal of clinical & experimental ophthalmology · 2015Article
- Determinants of patient satisfaction and function related to vision following cataract surgery in eyes with no visually consequential ocular co-morbidity.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2015Article
- Article
- The effect of pre-adapting light intensity on dark adaptation in early age-related macular degeneration.Documenta ophthalmologica. Advances in ophthalmology · 2013Article
- Rapid and reliable assessment of the contrast sensitivity function on an iPad.Investigative ophthalmology & visual science · 2013Article
- Evaluating Reading Performance in Different Preferred Retinal Loci in Persian-Speaking Patients with Age-Related Macular Degeneration.Journal of current ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose. To assess visual function and its response to serial intravitreal ranibizumab (Lucentis, Genentech) in patients with neovascular age-related macular degeneration (nv-AMD). Methods. Forty-seven eyes of 47 patients with nv-AMD, and corrected distance visual acuity (CDVA) logMAR 0.7 or better, undergoing intravitreal injections of ranibizumab, were enrolled into this prospective study. Visual function was assessed using a range of psychophysical tests, while mean foveal thickness (MFT) was determined by optical coherence tomography (OCT). Results. Group mean (±sd) MFT reduced significantly from baseline (233 (±59)) to exit (205 (±40)) (P = 0.001). CDVA exhibited no change between baseline and exit visits (P = 0.48 and P = 0.31, resp.). Measures of visual function that did exhibit statistically significant improvements (P < 0.05 for all) included reading acuity, reading speed, mesopic and photopic contrast sensitivity (CS), mesopic and photopic glare disability (GD), and retinotopic ocular sensitivity (ROS) at all eccentricities. Conclusion. Eyes with nv-AMD undergoing intravitreal ranibizumab injections exhibit improvements in many parameters of visual function. Outcome measures other than CDVA, such as CS, GD, and ROS, should not only be considered in the design of studies investigating nv-AMD, but also in treatment and retreatment strategies for patients with the condition.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.